ASX - By Stock
|
MSB |
Re:
Next steps discussion
|
|
NewInvestor12
|
52 |
21K |
3 |
02/10/20 |
02/10/20 |
ASX - By Stock
|
52
|
21K
|
3
|
|
ASX - By Stock
|
TRI |
Re:
Ann: FDA Strategy and Regulatory Update
|
|
NewInvestor12
|
692 |
202K |
1 |
30/09/20 |
30/09/20 |
ASX - By Stock
|
692
|
202K
|
1
|
|
ASX - By Stock
|
TRI |
Re:
Ann: FDA Strategy and Regulatory Update
|
|
NewInvestor12
|
692 |
202K |
2 |
30/09/20 |
30/09/20 |
ASX - By Stock
|
692
|
202K
|
2
|
|
ASX - By Stock
|
TRI |
Re:
MEBOB Options - Multi-bagger in the making
|
|
NewInvestor12
|
78 |
38K |
2 |
29/09/20 |
29/09/20 |
ASX - By Stock
|
78
|
38K
|
2
|
|
ASX - By Stock
|
TRI |
Re:
Ann: FDA Strategy and Regulatory Update
|
|
NewInvestor12
|
692 |
202K |
1 |
26/09/20 |
26/09/20 |
ASX - By Stock
|
692
|
202K
|
1
|
|
ASX - By Stock
|
TRI |
Re:
Ann: FDA Strategy and Regulatory Update
|
|
NewInvestor12
|
692 |
202K |
3 |
25/09/20 |
25/09/20 |
ASX - By Stock
|
692
|
202K
|
3
|
|
ASX - By Stock
|
TRI |
Re:
Ann: FDA Strategy and Regulatory Update
|
|
NewInvestor12
|
692 |
202K |
2 |
25/09/20 |
25/09/20 |
ASX - By Stock
|
692
|
202K
|
2
|
|
ASX - By Stock
|
KMD |
Re:
Ann: FY20 Final Results Presentation
|
|
NewInvestor12
|
34 |
14K |
1 |
23/09/20 |
23/09/20 |
ASX - By Stock
|
34
|
14K
|
1
|
|
ASX - By Stock
|
TRI |
Re:
Ann: FDA Strategy and Regulatory Update
|
|
NewInvestor12
|
692 |
202K |
2 |
21/09/20 |
21/09/20 |
ASX - By Stock
|
692
|
202K
|
2
|
|
ASX - By Stock
|
TRI |
Re:
Ann: FDA Strategy and Regulatory Update
|
|
NewInvestor12
|
692 |
202K |
3 |
21/09/20 |
21/09/20 |
ASX - By Stock
|
692
|
202K
|
3
|
|
ASX - By Stock
|
TRI |
Re:
Ann: FDA Strategy and Regulatory Update
|
|
NewInvestor12
|
692 |
202K |
5 |
21/09/20 |
21/09/20 |
ASX - By Stock
|
692
|
202K
|
5
|
|
ASX - By Stock
|
TRI |
Re:
Ann: FDA Strategy and Regulatory Update
|
|
NewInvestor12
|
692 |
202K |
5 |
21/09/20 |
21/09/20 |
ASX - By Stock
|
692
|
202K
|
5
|
|
ASX - By Stock
|
TRI |
Re:
Ann: FDA Strategy and Regulatory Update
|
|
NewInvestor12
|
692 |
202K |
3 |
21/09/20 |
21/09/20 |
ASX - By Stock
|
692
|
202K
|
3
|
|
ASX - By Stock
|
TRI |
Re:
MEB decision September quarter
|
|
NewInvestor12
|
63 |
21K |
5 |
18/08/20 |
18/08/20 |
ASX - By Stock
|
63
|
21K
|
5
|
|
ASX - By Stock
|
TRI |
Re:
Ann: Patent Granted to Monitor Stress Conditions Using Heartrate
|
|
NewInvestor12
|
55 |
19K |
1 |
11/08/20 |
11/08/20 |
ASX - By Stock
|
55
|
19K
|
1
|
|
ASX - By Stock
|
TRI |
Re:
Ann: Patent Granted to Monitor Stress Conditions Using Heartrate
|
|
NewInvestor12
|
55 |
19K |
1 |
11/08/20 |
11/08/20 |
ASX - By Stock
|
55
|
19K
|
1
|
|
ASX - By Stock
|
TRI |
Re:
Ann: Patent Granted to Monitor Stress Conditions Using Heartrate
|
|
NewInvestor12
|
55 |
19K |
2 |
10/08/20 |
10/08/20 |
ASX - By Stock
|
55
|
19K
|
2
|
|
ASX - By Stock
|
TRI |
Re:
Ann: Patent Granted to Monitor Stress Conditions Using Heartrate
|
|
NewInvestor12
|
55 |
19K |
2 |
10/08/20 |
10/08/20 |
ASX - By Stock
|
55
|
19K
|
2
|
|
ASX - By Stock
|
TRI |
Re:
Ann: Patent Granted to Monitor Stress Conditions Using Heartrate
|
|
NewInvestor12
|
55 |
19K |
1 |
10/08/20 |
10/08/20 |
ASX - By Stock
|
55
|
19K
|
1
|
|
ASX - By Stock
|
TRI |
Re:
Ann: FDA Strategy and Regulatory Update
|
|
NewInvestor12
|
163 |
48K |
0 |
07/08/20 |
07/08/20 |
ASX - By Stock
|
163
|
48K
|
0
|
|
ASX - By Stock
|
TRI |
Re:
Ann: FDA Strategy and Regulatory Update
|
|
NewInvestor12
|
163 |
48K |
2 |
07/08/20 |
07/08/20 |
ASX - By Stock
|
163
|
48K
|
2
|
|
ASX - By Stock
|
TRI |
Re:
Ann: FDA Strategy and Regulatory Update
|
|
NewInvestor12
|
163 |
48K |
0 |
07/08/20 |
07/08/20 |
ASX - By Stock
|
163
|
48K
|
0
|
|
ASX - By Stock
|
TRI |
Re:
Ann: FDA Strategy and Regulatory Update
|
|
NewInvestor12
|
163 |
48K |
4 |
07/08/20 |
07/08/20 |
ASX - By Stock
|
163
|
48K
|
4
|
|
ASX - By Stock
|
TRI |
Re:
Ann: FDA Strategy and Regulatory Update
|
|
NewInvestor12
|
163 |
48K |
6 |
07/08/20 |
07/08/20 |
ASX - By Stock
|
163
|
48K
|
6
|
|
ASX - By Stock
|
TRI Biotech |
Re:
FDA Approval - before 7 Aug 100 days 510K
|
|
NewInvestor12
|
187 |
71K |
5 |
07/08/20 |
07/08/20 |
ASX - By Stock
|
187
|
71K
|
5
|
|
ASX - By Stock
|
TRI Biotech |
Re:
FDA Approval - before 7 Aug 100 days 510K
|
|
NewInvestor12
|
187 |
71K |
0 |
07/08/20 |
07/08/20 |
ASX - By Stock
|
187
|
71K
|
0
|
|
ASX - By Stock
|
TRI Biotech |
Re:
FDA Approval - before 7 Aug 100 days 510K
|
|
NewInvestor12
|
187 |
71K |
1 |
07/08/20 |
07/08/20 |
ASX - By Stock
|
187
|
71K
|
1
|
|
ASX - By Stock
|
TRI Biotech |
Re:
FDA Approval - before 7 Aug 100 days 510K
|
|
NewInvestor12
|
187 |
71K |
5 |
06/08/20 |
06/08/20 |
ASX - By Stock
|
187
|
71K
|
5
|
|
ASX - By Stock
|
TRI Biotech |
Re:
FDA Approval - before 7 Aug 100 days 510K
|
|
NewInvestor12
|
187 |
71K |
3 |
06/08/20 |
06/08/20 |
ASX - By Stock
|
187
|
71K
|
3
|
|
ASX - By Stock
|
TRI |
Re:
MEBSLEEP Trademark Details
|
|
NewInvestor12
|
22 |
9.4K |
1 |
05/08/20 |
05/08/20 |
ASX - By Stock
|
22
|
9.4K
|
1
|
|
ASX - By Stock
|
TRI |
Re:
July 2020 clearance fda released
|
|
NewInvestor12
|
5 |
2.8K |
0 |
05/08/20 |
05/08/20 |
ASX - By Stock
|
5
|
2.8K
|
0
|
|
ASX - By Stock
|
TRI |
Re:
MEBSLEEP Trademark Details
|
|
NewInvestor12
|
22 |
9.4K |
0 |
05/08/20 |
05/08/20 |
ASX - By Stock
|
22
|
9.4K
|
0
|
|
ASX - By Stock
|
TRI |
Re:
MEBSLEEP Trademark Details
|
|
NewInvestor12
|
22 |
9.4K |
0 |
05/08/20 |
05/08/20 |
ASX - By Stock
|
22
|
9.4K
|
0
|
|
ASX - By Stock
|
TRI |
Re:
MEBSLEEP Trademark Details
|
|
NewInvestor12
|
22 |
9.4K |
2 |
05/08/20 |
05/08/20 |
ASX - By Stock
|
22
|
9.4K
|
2
|
|
ASX - By Stock
|
TRI |
Re:
MEBSLEEP Trademark Details
|
|
NewInvestor12
|
22 |
9.4K |
0 |
05/08/20 |
05/08/20 |
ASX - By Stock
|
22
|
9.4K
|
0
|
|
ASX - By Stock
|
TRI Biotech |
Re:
FDA Approval - before 7 Aug 100 days 510K
|
|
NewInvestor12
|
187 |
71K |
0 |
05/08/20 |
05/08/20 |
ASX - By Stock
|
187
|
71K
|
0
|
|
ASX - By Stock
|
TRI Biotech |
Re:
FDA Approval - before 7 Aug 100 days 510K
|
|
NewInvestor12
|
187 |
71K |
2 |
04/08/20 |
04/08/20 |
ASX - By Stock
|
187
|
71K
|
2
|
|
ASX - By Stock
|
TRI Biotech |
Re:
FDA Approval - before 7 Aug 100 days 510K
|
|
NewInvestor12
|
187 |
71K |
0 |
04/08/20 |
04/08/20 |
ASX - By Stock
|
187
|
71K
|
0
|
|
ASX - By Stock
|
TRI Biotech |
Re:
FDA Approval - before 7 Aug 100 days 510K
|
|
NewInvestor12
|
187 |
71K |
4 |
04/08/20 |
04/08/20 |
ASX - By Stock
|
187
|
71K
|
4
|
|
ASX - By Stock
|
TRI Biotech |
Re:
FDA Approval - before 7 Aug 100 days 510K
|
|
NewInvestor12
|
187 |
71K |
0 |
03/08/20 |
03/08/20 |
ASX - By Stock
|
187
|
71K
|
0
|
|
ASX - By Stock
|
TRI Biotech |
Re:
FDA Approval - before 7 Aug 100 days 510K
|
|
NewInvestor12
|
187 |
71K |
0 |
03/08/20 |
03/08/20 |
ASX - By Stock
|
187
|
71K
|
0
|
|
ASX - By Stock
|
TRI Biotech |
Re:
FDA Approval - before 7 Aug 100 days 510K
|
|
NewInvestor12
|
187 |
71K |
1 |
03/08/20 |
03/08/20 |
ASX - By Stock
|
187
|
71K
|
1
|
|
ASX - By Stock
|
TRI Biotech |
Re:
FDA Approval - before 7 Aug 100 days 510K
|
|
NewInvestor12
|
187 |
71K |
0 |
03/08/20 |
03/08/20 |
ASX - By Stock
|
187
|
71K
|
0
|
|
ASX - By Stock
|
TRI Biotech |
Re:
FDA Approval - before 7 Aug 100 days 510K
|
|
NewInvestor12
|
187 |
71K |
0 |
03/08/20 |
03/08/20 |
ASX - By Stock
|
187
|
71K
|
0
|
|
ASX - By Stock
|
TRI |
Re:
MEB chart
|
|
NewInvestor12
|
40 |
16K |
2 |
31/07/20 |
31/07/20 |
ASX - By Stock
|
40
|
16K
|
2
|
|
ASX - By Stock
|
TRI |
Re:
MEB chart
|
|
NewInvestor12
|
40 |
16K |
3 |
30/07/20 |
30/07/20 |
ASX - By Stock
|
40
|
16K
|
3
|
|
ASX - By Stock
|
TRI |
Re:
Ann: Medibio Quarterly Update and Cashflow Report
|
|
NewInvestor12
|
82 |
21K |
2 |
30/07/20 |
30/07/20 |
ASX - By Stock
|
82
|
21K
|
2
|
|
ASX - By Stock
|
TRI |
Re:
Ann: Medibio Quarterly Update and Cashflow Report
|
|
NewInvestor12
|
82 |
21K |
3 |
30/07/20 |
30/07/20 |
ASX - By Stock
|
82
|
21K
|
3
|
|
ASX - By Stock
|
TRI |
Re:
Ann: Medibio Quarterly Update and Cashflow Report
|
|
NewInvestor12
|
82 |
21K |
15 |
30/07/20 |
30/07/20 |
ASX - By Stock
|
82
|
21K
|
15
|
|
ASX - By Stock
|
TRI |
Re:
MEB chart
|
|
NewInvestor12
|
40 |
16K |
1 |
29/07/20 |
29/07/20 |
ASX - By Stock
|
40
|
16K
|
1
|
|